Should we reconsider dual antiplatelet therapy duration following bioresorbable scaffold angioplasty?

In the last years, the fourth revolution of interventional cardiology, represented by bioresorbable vascular scaffolds (BVS), became real. BVS’s prerogatives are a good radial force to counter back acute vessel recoil for the time needed, then a complete disappearance after few years. Latest generation drug-eluting stents (DES) showed that a reduction in dual antiplatelet therapy (DAPT) could be afforded if clinically needed without incurring in thrombotic events (1,2), even if the DAPT trial showed that a 2.5 years prolonged DAPT was associated with reduced myocardial infarction, stent thrombosis (ST) and MACE, at the expense of higher bleeding rates (3-